Benchling Launches New Products for Research Institutions and Biotech Startups to Accelerate Life Science Innovation

SAN FRANCISCO, Sept. 17, 2019 /PRNewswire/ — Benchling, the leading life sciences R&D cloud platform, today took a major step forward in democratizing access to its industry-leading data management and collaboration software by launching Benchling for Institutions and Benchling for Startups. The two new products are designed to advance major scientific discoveries where they happen most — research institutions, universities, medical centers, and innovative startups — giving these organizations access to a modern, cloud platform that frees them from busywork and helps them achieve results faster.

Academic institutions have become the main source of major breakthroughs in scientific techniques, such as CRISPR and next-generation sequencing. Biotech startups, meanwhile, are at the forefront of applying these techniques to develop life-changing products. With Benchling, organizations from academic institutions, to startups, to major enterprises can accelerate the pace at which they develop scientific breakthroughs, while minimizing time-consuming, antiquated processes. The Benchling platform enables scientists to manage the complexity of biology research and enhance collaboration across increasingly dispersed teams. And with their data and intellectual property in a modern, centralized platform, organizations can protect their discoveries, improve reproducibility, and back up business decisions with full scientific context.

  • Benchling for Institutions enables research organizations, universities and medical centers to offer Benchling to their research staff, delivering more efficient collaboration and empowering thousands of researchers to accelerate discovery. With Benchling, institutions can systematically protect and manage their intellectual property by centralizing recordkeeping, data tracking, and administration.
  • Benchling for Startups offers a core toolset from the Benchling platform for any early-stage life sciences research company at a dramatically reduced cost. Emerging biotechs can embrace good data management practices, ensure regulatory compliance, and back up pivotal early business decisions with data, all with the flexibility to scale their deployment as their company grows.

“Historically, academic institutions and biotech startups haven’t had access to cutting-edge scientific tools and software,” said Saji Wickramasekara, Benchling co-founder and CEO. “At Benchling, we’ve brought digital transformation to some of the world’s leading pharma and biotech companies with our R&D cloud platform. With these new products, we’re giving scientists at academic institutions and startups those same tools, so that they can advance the biology revolution and accelerate innovations – from CRISPR to lab-grown meat.”

Since launching in 2012, Benchling has grown to become the most widely adopted life science R&D cloud software used by over 175,000 scientists worldwide. Replacing outdated pen and paper processes, Benchling offers unified R&D solutions purpose-built for life sciences, including Notebook, Molecular Biology, Registry, Inventory, and Request & Workflow Management. Benchling is trusted by the world’s most renowned academic labs at Harvard, MIT, Stanford, and Berkeley, as well as by life science industry leaders such as Zoetis, Beam Therapeutics, Zymergen, and Regeneron Pharmaceuticals.

“The work we’re doing at Mammoth Biosciences grew out of academic research on CRISPR at the University of California, Berkeley,” said James Broughton, Senior Scientist at Mammoth Biosciences. “Now, we’re using that research to build the next generation of disease detection. Benchling is a key part of our strategy to scale our research and deliver on our innovations faster.”

About Benchling

Benchling is the first R&D cloud platform powering the life science industry and helping the next generation of scientists make breakthrough discoveries faster than ever before. Benchling is used by scientists globally across the largest multinational pharmaceutical corporations, emerging biotechnology companies, and major research institutions. For more information, please visit https://www.benchling.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/benchling-launches-new-products-for-research-institutions-and-biotech-startups-to-accelerate-life-science-innovation-300919440.html

SOURCE Benchling

Staff

Recent Posts

Judge Baker Children’s Center d/b/a The Baker Center for Children and Families Provides Notice of Data Security Incident

BOSTON, Dec. 27, 2024 /PRNewswire/ -- Judge Baker Children's Center d/b/a The Baker Center for…

4 hours ago

Glow Lifetech Grants Stock Options

Toronto, Ontario--(Newsfile Corp. - December 27, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

10 hours ago

Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company

RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…

10 hours ago

In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI

CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…

10 hours ago

NAVIGANTIS VASCO™ Robotic Platform Used with First Patients Enrolled in Neurovascular Study

MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…

10 hours ago

Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…

10 hours ago